<unk>  or SCIIT, is a therapeutic strategy employing rapid, specific,<unk>  term-modulation of the immune system using a therapeutic agent to induce T-cell non-responsiveness, also known as operational tolerance. As an alternative strategy to immunosuppression and antigen-specific tolerance inducing therapies, the primary goal of SCIIT is to re-establish or induce peripheral immune tolerance in the context of autoimmune disease and transplant rejection through the use of biological agents (compare also tolerogenic therapy). In recent years, SCIIT has received increasing attention in clinical and research settings as an alternative to immunosuppressive drugs currently used in the clinic, drugs which put the patients at risk of developing infection, cancer, and cardiovascular disease.
Short course immune induction therapy
Autologous immune enhancement therapy
T cell receptor T cell therapy
Donor lymphocyte infusion
Chemoimmunotherapy
Peripheral stem cell transplantation
Stem-cell therapy
Monoclonal antibody therapy